Refractory StudyRemember this is a refractory study. It's with the people that BCG doesn't work. That is why people should be licking their chops on this one. If this works , the next 800 patient study is in the bag because it goes head to head with BCG as a front line treatment and would be proven to work better than BCG already in the first study. I like it especially when the creator of BCG is on the Bioniche team.
Geez, another
.80 and I've broken even! Three years of hell with this stock finally over?
GLTA Longs
13PD